Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice
Fibrosis is a hallmark of chronic hypertension and disrupts the viability of human bone marrow-derived mesenchymal stromal cells (BM-MSCs) post-transplantation. This study thus, determined whether the anti-fibrotic drug, serelaxin (RLX), could enhance the therapeutic effects of BM-MSCs or BM-MSC-der...
Main Authors: | Yifang Li, Gang Zheng, Ekaterina Salimova, Brad R.S. Broughton, Sharon D. Ricardo, Michael de Veer, Chrishan S. Samuel |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-02-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222014585 |
Similar Items
-
Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease
by: Yifang Li, et al.
Published: (2022-05-01) -
The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy
by: Fariha Alam, et al.
Published: (2023-04-01) -
Relaxin-2 May Suppress Endometriosis by Reducing Fibrosis, Scar Formation, and Inflammation
by: Osamu Yoshino, et al.
Published: (2020-10-01) -
The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease
by: Ting‐Yun Chen, et al.
Published: (2020-04-01) -
Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism
by: Shuai Yuan, et al.
Published: (2023-04-01)